Immunotherapy-associated hemolytic anemia with pure red-cell aplasia: To the editor

New England Journal of Medicine

Volumn 374, Issue 11, 2016, Pages 1096-1097

  Nair, Ranjit ^a   Gheith, Shereen ^a   Nair, Suresh G ^a  

^a LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOGLOBULIN; PEMBROLIZUMAB; PREDNISONE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; BILATERAL PELVIC LYMPHADENOPATHY; BONE MARROW BIOPSY; CANCER IMMUNOTHERAPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMOLYTIC ANEMIA; HUMAN; HUMAN TISSUE; LETTER; LIP CANCER; LYMPHADENOPATHY; MELANOMA; MIDDLE AGED; PRIORITY JOURNAL; PURE RED CELL ANEMIA; ADVERSE EFFECTS; ANEMIA, HEMOLYTIC; ANTAGONISTS AND INHIBITORS; IMMUNOTHERAPY; RED-CELL APLASIA, PURE;

ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; CTLA-4 ANTIGEN; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOTHERAPY; MIDDLE AGED; RED-CELL APLASIA, PURE;

EID: 84961786652     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1509362     Document Type: Letter

References (5)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
2. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immunemediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009; 58: 1351-3.
3. Yervoy (ipilimumab). Princeton, NJ: Bristol-Myers Squibb, 2013 (package insert).
4. Keytruda (pembrolizumab). Whitehouse Station, NJ: Merck, 2015 (package insert).
5. Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune-or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 2005; 4: 264-9.